Literature DB >> 12414859

Angiogenesis in human normal and pathologic adrenal cortex.

G P Bernini1, A Moretti, A G Bonadio, M Menicagli, P Viacava, A G Naccarato, P Iacconi, P Miccoli, A Salvetti.   

Abstract

The angiogenic phenotype of 13 normal adrenal glands (N), 13 aldosterone-producing adenomas (APA), 12 cortisol-producing adenomas (CPA), 13 nonfunctioning adrenal cortical adenomas (NFA), and 13 adrenal cortical carcinomas (CA) was investigated. Intratumoral vascular density was explored by CD34, a marker of endothelial cells, and the angiogenic status was investigated by vascular endothelial growth factor (VEGF) expression, an important angiogenic factor expressed by tumoral cells. Vascular density, quantified as the number of vessels per square millimeter, was significantly lower (P < 0.0001) in CA (110.3 +/- 27.8) than in N (336.6 +/- 14.5), APA (322.8 +/- 19.1), CPA (288.5 +/- 14.3), and NFA (274.2 +/- 19.8). VEGF expression, calculated as the percentage of positive cells, was significantly greater (P < 0.0001) in CA (85.3 +/- 2.1) than in APA (56.5 +/- 7.5), CPA (38.5 +/- 7.0), N (33.1 +/- 6.1), and NFA (0.76 +/- 0.6). In APA, a negative relation between CD34 and plasma renin activity (P < 0.0002) and a positive association between CD34 and aldosterone levels (P < 0.05) was found. In conclusion, the angiogenic phenotype of CA is characterized by VEGF overexpression but low vascularization, a finding suggesting a dissociation between angiogenic potential and neoangiogenic capabilities of these tumors. The lack of VEGF expression in NFA and the close association between angiogenesis and functional status in APA also suggest a possible influence of the angiogenic phenotype on hormonal secretion of these endocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414859     DOI: 10.1210/jc.2001-011799

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Vascular endothelial growth factor localization in the adult.

Authors:  Arindel S R Maharaj; Magali Saint-Geniez; Angel E Maldonado; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

Review 2.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

Review 3.  Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour.

Authors:  N Garcia de la Torre; H E Turner; J A H Wass
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

4.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

5.  Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors.

Authors:  Sofia S Pereira; Madalena M Costa; Susana G Guerreiro; Mariana P Monteiro; Duarte Pignatelli
Journal:  Pathol Oncol Res       Date:  2017-07-10       Impact factor: 3.201

Review 6.  MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy.

Authors:  Peter Igaz; Ivan Igaz; Zoltán Nagy; Gábor Nyírő; Peter M Szabó; András Falus; Attila Patócs; Károly Rácz
Journal:  Cell Mol Life Sci       Date:  2014-10-09       Impact factor: 9.261

Review 7.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

8.  Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin.

Authors:  S Zacharieva; I Atanassova; M Orbetzova; G Kirilov; E Nachev; K Kalinov; R Shigarminova
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

Review 9.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

10.  Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia.

Authors:  Athar H Siddiqui; Roxanna A Irani; Weiru Zhang; Wei Wang; Sean C Blackwell; Rodney E Kellems; Yang Xia
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.